Scholars Central

Research articlePublished 6 Jun 2018

EFFICACY, SAFETY AND QUALITY OF LIFE OUTCOMES OF PALONOSETRON, RAMOSETRON AND GRANISETRON AS A PART OF ANTIEMETIC THERAPY IN PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING- A RANDOMISED COMPARATIVE TRIAL

Authors: Seema Gupta, Aman Sharma, Rahul Sharma, Dinesh Kumar, Nusrat Kreem Bhat, Vijay Khajuria

Journal of Evidence-Based Medicine and Healthcare

Volume 5 · Issue 24 · Pages 1–7

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

BACKGROUND 5-HT3 receptor antagonists have potent antiemetic effect in chemotherapy induced nausea and vomiting. The present study was conducted to study and compare the efficacy and safety of ramosetron, palonosetron and granisetron in preventing acute and delayed nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy, and the impact of these drugs on daily living of these patients. MATERIALS AND METHODS It was an open label, randomised, prospective, comparative, parallel study. A total of 59 patients were enrolled in the study. They were divided into 3 groups: palonosetron (0.25mg i.v and 0.5mg orally daily; n=18) group, ramosetron (0.3 mg i.v and 0.1 mg orally daily; n=22) group, and granisetron (1mg i.v and 2mg orally daily; n=19). The drugs were given for 5 days after chemotherapy cycle. In addition, all the three groups received inj. dexamethasone (16mg) prior to chemotherapy and tab. domperidone 10mg orally before chemotherapy and 3 times daily till day 5. The incidence and severity of nausea and vomiting, use of rescue antiemetics and the impact on daily living were evaluated for 7 days. Emetic episodes were recorded on a diary on a daily basis and nausea was measured on a visual analogue scale. Complete response rates (no emesis and no need of rescue antiemetics) were measured as the primary end point. The quality of life outcomes were measured using the functional life index – emesis (FLIE) questionnaire. Safety was evaluated by monitoring the adverse drug reactions of the test drugs. RESULTS The complete response rate in ramosetron group (72.7% in acute; 68.2% in delayed) were numerically better than palonosetron (66.7%; 61.1%) and granisetron (42.1%; 36.8%). The results didn’t achieve statistical significance. The impact on daily living was numerically better in ramosetron than palonosetron and granisetron but the results didn’t show a statistical significance. All the three drugs were well tolerated. CONCLUSION All the three drugs were effective and well tolerated. However, ramosetron showed numerically better complete response rates and better quality of life outcomes as compared to palonosetron and granisetron.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Evidence-Based Medicine and Healthcare.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Evidence-Based Medicine and Healthcare
  • SubjectNursing & Healthcare
  • BylineArticles whose byline prints “Seema Gupta”
  • BylineArticles whose byline prints “Aman Sharma”
  • BylineArticles whose byline prints “Rahul Sharma”
  • BylineArticles whose byline prints “Dinesh Kumar”
  • BylineArticles whose byline prints “Nusrat Kreem Bhat”
  • BylineArticles whose byline prints “Vijay Khajuria”